Nasdaq:US$18.31 (-0.90) | HKEX:HK$29.35 (-1.20) | AIM:£2.73 (-0.13)
搜索
新闻档案

通过选择所需的新闻类型，可以获得最新的公告或演示文稿。

请使用 「新闻主题」进一步挑选公告类别。
 

所有公告的全文可以PDF文件的形式下载。为方便起见，某些公告的部分或全部文字内容以网页的方式呈现。如存有任何不一致之处，请以PDF版本为准。

新闻类型
公告及新闻稿
演示文稿
新闻主题
其他业务
监管通知
肿瘤学 / 免疫学
集团
1234567891011
12
1314151617
找到相关结果： 826
公告及新闻稿, 监管通知 | 2016-08-09

Director's Share Dealing
London: Tuesday, August 9, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notification that the spouse of Mr Christopher Nash, Independent Non-executive Director, has purchased 3,120 and 42 ordinary shares of US
阅读更多
公告及新闻稿, 集团 | 2016-08-02

Change of Non-executive Directors
London: Tuesday, August 2, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces with effect from August 1, 2016, Dr Dan Eldar has been appointed as a Non-Executive Director of Chi-Med in place of Mr Salbaing who ha
阅读更多
公告及新闻稿, 集团 | 2016-08-02

Chi-Med Reports Interim Results for the Six Months Ended June 30, 2016, Provides 2016 Financial Guidance and Updates Shareholders on Key Clinical Programs
Group revenue up 27% to $104.5 million (H1 2015: $82.5m) and net income attributable to Chi‑Med of $0.5 million (H1 2015: $15.9m), reflecting a sharp increase in clinical investment.   Innovation Platform – Seven drug candidates in 25
阅读更多
公告及新闻稿, 肿瘤学 / 免疫学 | 2016-08-01

为加快沃利替尼全球研发项目，和黄医药与阿斯利康签署共同开发补充协议
首个以c-Met异常乳头状肾细胞癌（“PRCC”）为适应症的全球III期临床试验将于近期启动   2016年8月1日：和黄医药和阿斯利康今日宣布在2011年双方就沃利替尼达成的合作协议的基础上签
阅读更多
查看公告 (PDF)
公告及新闻稿, 集团 | 2016-07-05

Chi-Med to Announce 2016 Half-Year Financial Results
London: Tuesday, July 5, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will be announcing its interim results for the six months ended June 30, 2016 on Tuesday, August 2, 2016 at 7:00 am British Summer Time (BST). An a
阅读更多
公告及新闻稿, 监管通知 | 2016-06-29

Blocklisting Six Monthly Return
公告及新闻稿, 肿瘤学 / 免疫学 | 2016-06-20

和黄医药启动沃利替尼以EGFR突变非小细胞肺癌为适应症的全球II期临床试验
  扩展的非小细胞肺癌II期临床试验启动，阿斯利康向和黄医药支付1000万美元里程金 此研究的开展是基于沃利替尼早先与Tagrisso或Iressa联合用药治疗c-Met扩增非小细胞肺癌的初始小型II期
阅读更多
查看公告 (PDF)
公告及新闻稿, 监管通知 | 2016-06-15

Block Admission
London: Wednesday, June 15, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that an application has been made to the London Stock Exchange plc for a block admission of 1,000,000 ordinary shares, par value of U
阅读更多
公告及新闻稿, 监管通知 | 2016-05-31

Total Voting Rights
London: Tuesday, May 31, 2016: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at May 31, 2016, the issued share capital of Chi-Med consisted of 60,649,342 ordinary sha
阅读更多
公告及新闻稿, 肿瘤学 / 免疫学 | 2016-05-13

和黄医药完成呋喹替尼以结直肠癌为适应症的III期临床试验的患者入组工作，共招募416名患者
2016年5月13日：和黄医药今日宣布呋喹替尼（HMPL-013）以结直肠癌为适应症的III期临床试验“FRESCO”顺利完成患者入组工作。2012年，中国新发结直肠癌病例约为39万例，呋喹替尼的这项关键性I
阅读更多
查看公告 (PDF)
公告及新闻稿, 监管通知 | 2016-04-29

Total Voting Rights
London: Friday, April 29, 2016: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at April 29, 2016, the issued share capital of Chi-Med consisted of 60,639,926 ordinary
阅读更多
公告及新闻稿, 监管通知 | 2016-04-27

Results of Annual General Meeting
London: Wednesday, April 27, 2016: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that all ordinary resolutions and the special resolution put to its Annual General Meeting ("AGM") held on April 27, 2016 were duly pas
阅读更多
公告及新闻稿, 集团 | 2016-04-13

Hutchison China MediTech Limited Announces Exercise of Overallotment Option
London: Wednesday, April 13, 2016: Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) announces that the underwriters of its offering of American depositary shares (“ADSs”) on the Nasdaq Global Select Market (the “Offering”) have
阅读更多
公告及新闻稿, 肿瘤学 / 免疫学 | 2016-04-12

Chi-Med initiates first-in-human clinical trial of novel PI3K inhibitor HMPL-689
London: Tuesday, April 12, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has initiated the first-in-human (“FIH”) Phase I cli
阅读更多
公告及新闻稿, 监管通知 | 2016-03-31

Total Voting Rights
London: Thursday, March 31, 2016: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at March 31, 2016, the issued share capital of Chi-Med consisted of 60,283,118 ordinary
阅读更多
公告及新闻稿, 监管通知 | 2016-03-29

Director's Shareholding
London: Tuesday, March 29, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM / Nasdaq: HCM) received notification on March 25, 2016 that Mr Christian Hogg, Executive Director and Chief Executive Officer, has purchased 36,600 American Deposi
阅读更多
公告及新闻稿, 监管通知 | 2016-03-23

Holding(s) in Company
  For filings with the FCA include the annex For filings with issuer exclude the annex TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying is
阅读更多
公告及新闻稿, 新闻稿, 集团 | 2016-03-22

Closing of U.S. Public Offering of ADSs Raising Approximately US$101 Million on the Nasdaq Stock Market
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEMINATION IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTIT
阅读更多
公告及新闻稿, 监管通知 | 2016-03-21

Director's Shareholding
London: Monday, March 21, 2016: Hutchison China MediTech Limited ("Chi-Med") (AIM / Nasdaq: HCM) received notification on 18 March 2016 that Ms Edith Shih, Non-executive Director, has purchased 40,741 American Depositary Shares ("ADSs", each represen
阅读更多
公告及新闻稿, 肿瘤学 / 免疫学 | 2016-03-21

Chi-Med initiates sulfatinib Phase III registration study in pancreatic neuroendocrine tumor patients
London: Monday, March 21, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has initiated SANET-p, a Phase III registration trial of s
阅读更多
公告及新闻稿, 集团 | 2016-03-18

Final Prospectus
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEMINATION IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTIT
阅读更多
公告及新闻稿, 集团 | 2016-03-17

Pricing of U.S. Public Offering of ADSs
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEMINATION IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONS
阅读更多
公告及新闻稿, 新闻报道, 集团 | 2016-03-17

Hutchison China MediTech Limited Announces Pricing of U.S. Public Offering of ADSs
Press Release London: Wednesday, March 16, 2016: Hutchison China MediTech Limited ("Chi Med") (AIM: HCM) announces the pricing of its U.S. public offering of American depositary shares (“ADSs”) (the “Offering”), raising gross proceeds of app
阅读更多
公告及新闻稿, 集团 | 2016-03-15

2015 Annual Report and Notice of Annual General Meeting
London: Tuesday, March 15, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM:HCM) today announces that its 2015 Annual Report together with the Notice of Annual General Meeting and the Form of Proxy have been posted to shareholders. The
阅读更多
公告及新闻稿, 集团 | 2016-03-07

Repeat of Announcement of Fifth Public Filing of Registration Statement on Form F-1 and Launch of Potential U.S. Public Offering of ADSs
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEMINATION IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTIT
阅读更多
公告及新闻稿, 集团 | 2016-03-04

Hutchison China MediTech Limited Announces Launch of Potential U.S. Public Offering of ADSs
Press Release London: Friday, 4 March 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) announces that it intends to offer and sell, subject to market and other conditions, approximately $100 million of its ordinary shares in the f
阅读更多
公告及新闻稿, 集团 | 2016-03-04

Fifth Public Filing of Registration Statement on Form F-1 and Launch of Potential U.S. Public Offering of ADSs
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEMINATION IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTIT
阅读更多
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2016-03-02

和黄医药启动索凡替尼以甲状腺癌为适应症的II期临床研究
2016年3月2日：和黄医药今日宣布正式启动索凡替尼（HMPL-012）以局部晚期或放射性碘难治性转移分化的甲状腺癌（DTC）或甲状腺髓样癌（MTC）为适应症在中国开展的一项开放式II期临床研究，
阅读更多
下载新闻稿 (PDF)
公告及新闻稿, 集团 | 2016-03-01

Fourth Public Filing of Registration Statement on Form F-1 for potential Nasdaq Stock Market Listing
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEMINATION IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTIT
阅读更多
公告及新闻稿, 集团 | 2016-03-01

Final Results for the year ended 31 December 2015
Record profit from operations at both Group and Commercial Platform levels Excellent progress on all lead drug candidates – five out of five positive Phase Ib/II outcomes in 2015 Seven drug candidates – 19 active clinical trials – 3 Phase III
阅读更多
公告及新闻稿, 集团 | 2016-02-11

Third Public Filing of Registration Statement on Form F-1 for potential Nasdaq Stock Market Listing
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEMINATION IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTIT
阅读更多
公告及新闻稿, 监管通知 | 2016-01-29

Notice of Announcement of 2015 Final Results
London: Friday, 29 January 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM:HCM) will be announcing its final results for the year ended 31 December 2015 on Tuesday, 1 March 2016.  An analyst presentation will be held at 9:00 am on the
阅读更多
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2016-01-15

和黄医药在澳大利亚启动HMPL-523以血液肿瘤为适应症的I期临床试验
2016年1月15日：和黄医药今日宣布在澳大利亚启动HMPL-523以恶性血液肿瘤为适应症的I期临床试验。HMPL-523是针对B细胞受体信号通路中的酪氨酸激酶Syk的新型高选择性小分子抑制剂。此次研究的
阅读更多
下载新闻稿 (PDF)
公告及新闻稿, 监管通知 | 2015-12-29

Blocklisting Six Monthly Return
London: Tuesday, 29 December 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) announces the following blocklisting six monthly return:   1. Name of applicant: Hutchison China MediTech Limited   2. Name of scheme: Hutc
阅读更多
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2015-12-18

和黄医药启动索凡替尼以神经内分泌瘤为适应症的III期临床研究
2015年12月18日：和黄医药今日宣布正式启动索凡替尼（HMPL-012）以非胰腺神经内分泌瘤为适应症的中国III期临床研究（SANET-ep）。此次研究的受试者均为非胰腺神经内分泌瘤患者，包括原发于
阅读更多
下载新闻稿 (PDF)
公告及新闻稿, 其他业务, 新闻稿 | 2015-12-09

US$105 million Shanghai land compensation agreement
Press Release London: Wednesday, 9 December 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Shanghai Hutchison Pharmaceuticals Limited (“SHPL”), its 50:50 joint venture with a subsidiary of Shanghai Pharma
阅读更多
公告及新闻稿, 肿瘤学 / 免疫学 | 2015-12-08

和黄医药启动呋喹替尼以非小细胞肺癌为适应症的III期临床试验
2015年12月8日: 和黄医药今日宣布呋喹替尼（HMPL-013）以晚期非鳞状非小细胞肺癌为适应症的中国III期临床试验（FALUCA）正式启动。呋喹替尼是一种新型高选择性抑制血管细胞内皮生长因子受
阅读更多
查看公告 (PDF)
公告及新闻稿, 集团 | 2015-11-13

Second Public Filing of Registration Statement on Form F‑1 for potential Nasdaq Stock Market Listing
The following includes the text of the Announcement, excluding the appendix. For the complete Announcement, please download the PDF. --- NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEM
阅读更多
公告及新闻稿, 监管通知 | 2015-11-10

Results of Extraordinary General Meeting
London: Tuesday, 10 November 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that the ordinary resolution and the special resolution put to its Extraordinary General Meeting held on 10 November 2015 (“EGM”) were
阅读更多
公告及新闻稿, 监管通知 | 2015-11-09

Director's Share Dealing
London: Monday, 9 November 2015: Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) hereby makes the following amendments to the "Director's Share Dealing" announcement released on 20 October 2015 subsequent to the notification received from Mr
阅读更多
公告及新闻稿, 肿瘤学 / 免疫学 | 2015-11-06

和黄医药启动索凡替尼在美国的临床试验
2015年11月6日：和黄医药今日宣布启动索凡替尼（HMPL-012）在美国的I期临床试验。该药的美国新药临床研究申请于今年递交并通过，2015年11月4日首位受试者接受给药治疗。此外，和黄医药将
阅读更多
查看公告 (PDF)
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2015-10-30

Sulfatinib clinical results and fruquintinib-savolitinib combination preclinical results to be presented at the 2015 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference
 Press Release London: Friday, 30 October 2015: Hutchison China MediTech Limited (“Chi‑Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, will present further scientific data on sulfa
阅读更多
公告及新闻稿, 监管通知 | 2015-10-30

Total Voting Rights
London: Friday, 30 October 2015: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) hereby notifies the market that as at 30 October 2015, the issued share capital of Chi-Med consisted of 56,533,118 ordinary shares
阅读更多
公告及新闻稿, 肿瘤学 / 免疫学 | 2015-10-30

和黄医药宣布新型Syk抑制剂HMPL-523治疗免疫疾病的I期临床试验取得成功
2015年10月30日:  和黄医药（上海）有限公司（简称 “和黄医药” ）今日宣布成功完成HMPL‑523的I期临床试验。HMPL-523是针对B细胞受体信号通路中的酪氨酸激酶Syk的新型高选择性小分子抑制剂
阅读更多
查看公告 (PDF)
公告及新闻稿, 肿瘤学 / 免疫学 | 2015-10-23

Proof-of-concept study of fruquintinib in non-small cell lung cancer triggers milestone payment
London: Friday, 23 October 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, is set to receive a US$10 million milestone payment, in the fourt
阅读更多
公告及新闻稿, 监管通知 | 2015-10-20

Director's Share Dealing
London: Tuesday, 20 October 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) received notification on 19 October 2015 that Mr Christopher Nash, Independent Non-executive Director, has: purchased jointly with his spouse 4,512 ordi
阅读更多
公告及新闻稿, 监管通知 | 2015-10-19

Awards under Long Term Incentive Plan
London: Monday, 19 October 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) announces that the Remuneration Committee of Chi-Med today granted conditional awards (the “LTIP Awards”) under the Long Term Incentive Plan (the “LTIP
阅读更多
公告及新闻稿, 新闻稿, 集团 | 2015-10-16

Hutchison China MediTech Limited Files Registration Statement for Potential Nasdaq Stock Market Listing
Press Release London: Friday, 16 October 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) announces that it has publicly filed today a registration statement on Form F-1 (the "Registration Statement") with the United States Securiti
阅读更多
公告及新闻稿, 集团 | 2015-10-16

Shareholders' Circular and Notice of Extraordinary General Meeting
London: Friday, 16 October 2015: Hutchison China MediTech Limited ("Chi-Med”) (AIM: HCM) today announces that, following the announcement that it had publicly filed a registration statement on Form F-1 ("Form F-1 Registration Statement") with the U
阅读更多
公告及新闻稿, 集团 | 2015-10-16

Filing of Registration Statement on Form F-1 for potential Nasdaq Stock Market Listing
The following includes the text of the Announcement but excludes the appendix. For the complete release, please download the PDF. --- NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEM
阅读更多
1234567891011
12
1314151617